NCT00002226已完成不适用
A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma
SUGEN7 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 7
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
详细描述
Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You may be eligible for this study if you:
- •Are at least 18 years old.
- •Are HIV-positive.
- •Have KS with at least 5 skin lesions.
- •Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.
- •Agree to use effective methods of birth control during the study.
排除标准
- •You will not be eligible for this study if you:
- •Have had surgery within 4 weeks of study entry.
- •Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.
- •Have pulmonary KS (KS in your lungs).
- •Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.
- •Are allergic to Cremophor.
- •Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).
- •Are pregnant.
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected PatientsHIV InfectionsNCT00002375Merck Sharp & Dohme LLC24
Unknown
1 期
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV TherapyHIV InfectionsNCT00002449Chiron Corporation212
已完成
1 期
Safety and Efficacy of BAY 50-4798 in Patients With HIV InfectionHIV InfectionsNCT00059462Bayer56
已完成
4 期
Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentHIV InfectionsNCT00005018Glaxo Wellcome150
已完成
2 期
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentSarcoma, KaposiHIV InfectionsNCT00005931SUGEN30